Last reviewed · How we verify
transdermal nicotine replacement therapy
At a glance
| Generic name | transdermal nicotine replacement therapy |
|---|---|
| Also known as | NRT, nicotine patch |
| Sponsor | Duke University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- iCanQuit Smoking Cessation Among Hispanic Adults (PHASE3)
- Project DEDUCE: Digital Envirotyping to Develop Understanding of Cigarette Smoking and the Environment (PHASE4)
- STEPS: Substance Use Trial of E-cigarettes or Pharmacotherapy for Smoking (NA)
- Comparing Two Behavioral Approaches to Quitting Smoking in Mental Health Settings (NA)
- Tobacco Treatment Optimization and Preferences During Concurrent Cancer Treatment (PHASE2)
- Tobacco Cessation in Public Housing (NA)
- Remote vs. In-Person Study Evaluation (RISE) Trials: RISE Above Smoking (Trial 1) (PHASE2, PHASE3)
- Behavioral Activation Therapy and Nicotine Replacement Therapy in Increasing Smoking Cessation (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- transdermal nicotine replacement therapy CI brief — competitive landscape report
- transdermal nicotine replacement therapy updates RSS · CI watch RSS
- Duke University portfolio CI